InsiderTrades.com logo
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now
Graham Griffiths net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Graham Griffiths Biography and Net Worth

Insider of Vaccitech
Graham joined Vaccitech as Chief Business Officer in October 2017. Previously he was COO and co-founder of Agalimmune Limited, a clinical stage Biotech developing directly administered immunotherapies for oncology indications.

Graham qualified as a solicitor in London in 2005, before moving to co-found technology company MET, which was subsequently sold to a group of private investors. He was an investment fund manager at Matrix Securities and then worked for 9 years as an operator and investor to develop a portfolio of life sciences companies held by Animatrix Capital LLP. Graham’s focus has been on operating and developing early stage products and companies targeting the diagnosis and treatment of cancer and infectious diseases. One of these was Agalimmune, where Graham led the licensing, funding and development of a novel cancer immunotherapy and played a lead role in the company’s successful sale to NASDAQ-listed BioLineRx in 2017. Graham holds a BA Hons degree in Law with French from Newcastle University.

What is Graham Griffiths' net worth?

The estimated net worth of Graham Griffiths is at least $253,113.24 as of August 25th, 2022. Mr. Griffiths owns 104,209 shares of Vaccitech stock worth more than $253,113 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Griffiths may own. Learn More about Graham Griffiths' net worth.

How old is Graham Griffiths?

Mr. Griffiths is currently 44 years old. There are 4 older executives and no younger executives at Vaccitech. The oldest executive at Vaccitech is Mr. Chris Ellis, Chief Operating Officer, who is 63 years old. Learn More on Graham Griffiths' age.

How do I contact Graham Griffiths?

The corporate mailing address for Mr. Griffiths and other Vaccitech executives is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. Vaccitech can also be reached via phone at 44-18-6581-8808 and via email at [email protected].. Learn More on Graham Griffiths' contact information.

Has Graham Griffiths been buying or selling shares of Vaccitech?

Graham Griffiths has not been actively trading shares of Vaccitech in the last ninety days. Most recently, Graham Griffiths sold 10,000 shares of the business's stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $7.39, for a transaction totalling $73,900.00. Following the completion of the sale, the insider now directly owns 104,209 shares of the company's stock, valued at $770,104.51. Learn More on Graham Griffiths' trading history.

Who are Vaccitech's active insiders?

Vaccitech's insider roster includes Karen Dawes (Director), Christopher Ellis (COO), Graham Griffiths (Insider), and Robin Wright (Director). Learn More on Vaccitech's active insiders.

Are insiders buying or selling shares of Vaccitech?

During the last year, Vaccitech insiders bought shares 2 times. They purchased a total of 23,750 shares worth more than $60,975.00. The most recent insider tranaction occured on June, 26th when Director Joseph Scheeren bought 10,000 shares worth more than $24,400.00. Insiders at Vaccitech own 6.0% of the company. Learn More about insider trades at Vaccitech.

Information on this page was last updated on 6/26/2023.

Graham Griffiths Insider Trading History at Vaccitech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2022Sell10,000$7.39$73,900.00104,209View SEC Filing Icon  
8/17/2022Sell500$4.76$2,380.00114,209View SEC Filing Icon  
8/12/2022Sell5,000$4.50$22,500.00118,329View SEC Filing Icon  
6/23/2022Sell8$5.28$42.24123,229View SEC Filing Icon  
5/4/2021Buy100$17.00$1,700.00100View SEC Filing Icon  
See Full Table

Graham Griffiths Buying and Selling Activity at Vaccitech

This chart shows Graham Griffiths's buying and selling at Vaccitech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaccitech Company Overview

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $2.43
Low: $2.40
High: $2.54

50 Day Range

MA: $2.71
Low: $2.33
High: $3.67

2 Week Range

Now: $2.43
Low: $1.64
High: $5.10

Volume

2,824 shs

Average Volume

244,643 shs

Market Capitalization

$93.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now